streep tussen2


Launched at an event in the European Parliament today,

the ACHIEVE (short for Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe)

coalition calls on the EU to take action to eliminate viral hepatitis B and C by 2030 in the WHO European Region, in line with the WHO Global Health Sector Strategy on viral hepatitis, the WHO Europe Action Plan, which build on and the UN Sustainable Development Goals (SDGs).

The ACHIEVE coalition includes the following organisations: The European Liver Patients’ Association (ELPA), the Viral Hepatitis Prevention Board, Hepatitis B and C Public Policy Association, EASL International Liver Foundation, European Aids Treatment Group (EATG), Correlation Network, the World Hepatitis Alliance and the Barcelona Institute for Global Health (ISGlobal). It is enabled by the support of Abbott, CEPHEID, Gilead Sciences and MSD.

IMG 7267

IMG 7297

For more information


streep tussen2


Correlation Network together with a number of partners

organised a Hepatitis C Community Summit in April 2017 in Amsterdam because this is a historic moment for hepatitis C treatment. With the advent of direct-acting antivirals (DAAs) we can now massively reduce the harm from an infectious disease that affects millions of people and causes hundreds of thousands of unnecessary deaths every year. Interferon-free DAA regimes are short, highly tolerable and simple to deliver, with cure rates of over 90%.

Hepatitis C elimination will on the one hand require an enormous scale-up in testing and treatment, along with comprehensive harm reduction services, including in prisons and on the other hand a sustained collaborative effort to combat the stigma, discrimination and criminalisation faced by people who inject drugs, and other priority communities, like migrants and men having sex with men.

Communities, harm reduction and community representatives must participate in formulating and implementing hepatitis C prevention, testing and treatment strategies because these stakeholders have unique knowledge about what will be accessible, acceptable and effective. Without their close ongoing involvement, the effort to eliminate hepatitis C is likely to fail.

The video highlights the most important aspects of the Community Summit and relevant topics to address for Hepatitis C elimination.

For more information

streep tussen2


Hepatitis C Civil Society

Declaration launched

At the Hepatitis C Community Summit in Amsterdam, civil society and community organisations from all over Europe launched a declaration to address the urgent need for civil society involvement in HCV policy and practice. Only with the collaboration of all and by combating stigma and discrimination, can the elimination of HCV be a realistic goal.

Please read the declaration here and share widely


streep tussen2


HCV Community Summit

18-19 April in Amsterdam

hepc summit amsterdamEradication of hepatitis C asks for Community Involvement
With the new medicines now available an opportunity exists to completely eradicate
hepatitis C. However, it will require pharmaceutical companies, governments, doctors,
and health purchasers to come together to ensure these medicines are quickly available
to all. Also a crucial factor for success will be the involvement of people living with
hepatitis C and well-resourced harm reduction services.

The summit will bring together experts and representatives to discuss the needs, gaps
and opportunities to make treatment available for all people in need. Also to present
community approaches for testing and treatment for HCV (and B) and to discuss/agree
on further community action and advocacy.

The summit will also reach out to attendees of the International Lever Congress, organised by EASL at the same time.

Please consult


streep tussen2


Hepatitis B and C testing: Why? Who? How?

A guidance paper on testing in community and harm reduction settings

testing paper webThis paper aims to stimulate services to engage in HCV and HBV awareness raising and in particular to inform community members, social and health care practitioners about current HBV/HCV testing and diagnosis methods, screening technologies and other aspects around the issue.





streep tussen2

The aims of the Correlation Berlin Hepatitis C Manifesto:

Did dreams come true?

Access to prevention, testing, treatment and care for people who use drugs

Eberhard Schatz, Katrin Schiffer, Mags Maher, Magdalena Harris, Xavier Major Roca,
Mojca Maticic and Astrid Leicht


streep tussen2


Urgent action to fight hepatitis C in people

who inject drugs in Europe

John F. Dillon, Jeffrey V. Lazarus and Homie A. Razavi



streep tussen2


The time to foster a unified global response

to the hepatitis C epidemic is now!

  • Develop Targeted HCV Strategies and Action Plans
  • Provide Access to HCV Testing, Treatment and Care Services
  • Scale-up Harm Reduction, evidence and rights and Community-Based Programs
  • Decriminalize People Who Use Drugs
  • Meaningful inclusion of People who Inject Drugs and their organisations
  • Increase Health and HCV Literacy



streep tussen2


Hepatitis C among drug users in Europe:

epidemiology, treatment and prevention

EMCDDA, Lisbon, July 2016

HepC insights cover pageEMCDDA published a new INSIGHT report: epidemiology, treatment and prevention provides a timely contribution to raising awareness of the hepatitis C epidemic in Europe and the opportunities now opening up to tackle this problem decisively. A state of the art review of the epidemiology of hepatitis C virus (HCV) infection in Europe and an overview of the way preventive measures are currently implemented in European countries set the scene. International experts address the treatment of HCV infection among people who inject drugs, with an emphasis on how we encourage uptake and deliver effective outcomes. Implementation issues are also explored, as are the complementary roles of treatment and prevention. The new medicines and treatment regimens driving the transformation in the HCV treatment landscape are reviewed in detail. The challenges of scaling up HCV treatment and successfully involving drug using patients is explored from different viewpoints, including that of the drug user.

Read more: